Abstract: There is disclosed patient derived xenograft (PDXs) cells/systems/models and/or derivatives, parental (unlabelled) and/or labelled, expressing a fluorescent protein or a luciferase, or a combination thereof; for evaluating therapies comprising nasopharyngeal carcinoma (EBV positive and/or EBV negative). In another embodiment, there is disclosed a method of evaluating the efficacy of an agent used to treat nasopharyngeal carcinoma (NPC) comprising: preparing a non-human model; whereby the non-human model carries cells from NPC xenograft; labelling the cells from the NPC xenograft with gfp-luc2 marker using a lentiviral vector system; and growing the cells in short term in vitro culture; including adaptation of said culture into multi-well plates for use in further screening and/or evaluation assays; wherein the NPC xenograft is PDX.